Company / R&D Expense
LIPELLA PHARMACEUTICALS INC. R&D Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$3.6M
FY2024
5-year range
$2.5M / $3.6M
FY2022-FY2024
Trend
+18.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2024.
Improved from $3M to $4M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, r&d expense increased 18.9% year-over-year.
Company context
Key Data Points
- Altman Z-Score -8.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.6M | +18.9% |
| FY2023 | $3.0M | +19.3% |
| FY2022 | $2.5M | - |
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026